# Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)

> **NCT06106282** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 105 (actual)

## Conditions studied

- Anatomic Stage 0 Breast Cancer AJCC v8
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Hormone Receptor-Positive Breast Carcinoma

## Interventions

- **OTHER:** Non-Interventional Study

## Key facts

- **NCT ID:** NCT06106282
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-12
- **Primary completion:** 2025-10-27
- **Final completion:** 2025-10-27
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2025-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06106282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06106282, "Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06106282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*